Histogen Inc., a San Diego-based regenerative medicine startup, has held a $5.35 million first close on its Series A round. Backers include Secure Medical Inc., CellCeuticals Skin Care Inc. and Leonard Lavin (founder of Alberto-Culver Co.).
Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn fibroblasts, today announced the initial close of Series A financing at $5.35 million. The round was completed by private and corporate investors, including Secure Medical Inc., CellCeuticals Skin Care Inc., and Leonard H. Lavin, founder and Chairman Emeritus of the Alberto-Culver Company.
Histogen will utilize the round to fund Phase 1 clinical trials for hair growth and complete 510k submissions for wound and hernia repair applications. The round will also enable the Company to upscale manufacturing for Exceltrix